Stock Information

At the end of 2024, with the discontinuation of the Phase 3 studies of REL-1017 in major depressive disorders, we made the exploration of strategic product acquisitions our primary focus.  We initiated a process to transform the Company through strategic product acquisition efforts to maximize shareholder value. 

Currently, Relmada is focused on three priorities:

• Progressing our product pipeline including NDV-01 and sepranolone
• Exploring product acquisitions opportunities to maximize shareholder value
• Maintaining careful resource prioritization